302 related articles for article (PubMed ID: 29406859)
1. Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.
Seijkens TTP; van Tiel CM; Kusters PJH; Atzler D; Soehnlein O; Zarzycka B; Aarts SABM; Lameijer M; Gijbels MJ; Beckers L; den Toom M; Slütter B; Kuiper J; Duchene J; Aslani M; Megens RTA; van 't Veer C; Kooij G; Schrijver R; Hoeksema MA; Boon L; Fay F; Tang J; Baxter S; Jongejan A; Moerland PD; Vriend G; Bleijlevens B; Fisher EA; Duivenvoorden R; Gerdes N; de Winther MPJ; Nicolaes GA; Mulder WJM; Weber C; Lutgens E
J Am Coll Cardiol; 2018 Feb; 71(5):527-542. PubMed ID: 29406859
[TBL] [Abstract][Full Text] [Related]
2. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.
Lutgens E; Lievens D; Beckers L; Wijnands E; Soehnlein O; Zernecke A; Seijkens T; Engel D; Cleutjens J; Keller AM; Naik SH; Boon L; Oufella HA; Mallat Z; Ahonen CL; Noelle RJ; de Winther MP; Daemen MJ; Biessen EA; Weber C
J Exp Med; 2010 Feb; 207(2):391-404. PubMed ID: 20100871
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.
Aarts SABM; Seijkens TTP; Kusters PJH; van der Pol SMA; Zarzycka B; Heijnen PDAM; Beckers L; den Toom M; Gijbels MJJ; Boon L; Weber C; de Vries HE; Nicolaes GAF; Dijkstra CD; Kooij G; Lutgens E
J Neuroinflammation; 2017 May; 14(1):105. PubMed ID: 28494768
[TBL] [Abstract][Full Text] [Related]
4. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice.
van den Berg SM; Seijkens TT; Kusters PJ; Zarzycka B; Beckers L; den Toom M; Gijbels MJ; Chatzigeorgiou A; Weber C; de Winther MP; Chavakis T; Nicolaes GA; Lutgens E
Int J Obes (Lond); 2015 May; 39(5):782-90. PubMed ID: 25394307
[TBL] [Abstract][Full Text] [Related]
5. Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes.
Gerdes N; Seijkens T; Lievens D; Kuijpers MJ; Winkels H; Projahn D; Hartwig H; Beckers L; Megens RT; Boon L; Noelle RJ; Soehnlein O; Heemskerk JW; Weber C; Lutgens E
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):482-90. PubMed ID: 26821950
[TBL] [Abstract][Full Text] [Related]
6. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells.
Zirlik A; Bavendiek U; Libby P; MacFarlane L; Gerdes N; Jagielska J; Ernst S; Aikawa M; Nakano H; Tsitsikov E; Schönbeck U
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1101-7. PubMed ID: 17332487
[TBL] [Abstract][Full Text] [Related]
7. The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE
Xiong W; Wang X; Dai D; Zhang B; Lu L; Tao R
Thromb Haemost; 2017 Jan; 117(2):401-414. PubMed ID: 27831589
[TBL] [Abstract][Full Text] [Related]
8. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages.
Mukundan L; Bishop GA; Head KZ; Zhang L; Wahl LM; Suttles J
J Immunol; 2005 Jan; 174(2):1081-90. PubMed ID: 15634933
[TBL] [Abstract][Full Text] [Related]
9. nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe
Lallemand T; Rouahi M; Swiader A; Grazide MH; Geoffre N; Alayrac P; Recazens E; Coste A; Salvayre R; Nègre-Salvayre A; Augé N
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1479-1492. PubMed ID: 29794115
[TBL] [Abstract][Full Text] [Related]
10. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.
Pullen SS; Labadia ME; Ingraham RH; McWhirter SM; Everdeen DS; Alber T; Crute JJ; Kehry MR
Biochemistry; 1999 Aug; 38(31):10168-77. PubMed ID: 10433725
[TBL] [Abstract][Full Text] [Related]
11. Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.
Hueso M; De Ramon L; Navarro E; Ripoll E; Cruzado JM; Grinyo JM; Torras J
Atherosclerosis; 2016 Dec; 255():80-89. PubMed ID: 27835742
[TBL] [Abstract][Full Text] [Related]
12. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.
Zirlik A; Maier C; Gerdes N; MacFarlane L; Soosairajah J; Bavendiek U; Ahrens I; Ernst S; Bassler N; Missiou A; Patko Z; Aikawa M; Schönbeck U; Bode C; Libby P; Peter K
Circulation; 2007 Mar; 115(12):1571-80. PubMed ID: 17372166
[TBL] [Abstract][Full Text] [Related]
13. Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition.
Zhu L; Giunzioni I; Tavori H; Covarrubias R; Ding L; Zhang Y; Ormseth M; Major AS; Stafford JM; Linton MF; Fazio S
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1483-95. PubMed ID: 27365402
[TBL] [Abstract][Full Text] [Related]
14. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization.
Pullen SS; Miller HG; Everdeen DS; Dang TT; Crute JJ; Kehry MR
Biochemistry; 1998 Aug; 37(34):11836-45. PubMed ID: 9718306
[TBL] [Abstract][Full Text] [Related]
15. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.
Hauer J; Püschner S; Ramakrishnan P; Simon U; Bongers M; Federle C; Engelmann H
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2874-9. PubMed ID: 15708970
[TBL] [Abstract][Full Text] [Related]
16. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.
Lievens D; Eijgelaar WJ; Biessen EA; Daemen MJ; Lutgens E
Thromb Haemost; 2009 Aug; 102(2):206-14. PubMed ID: 19652870
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.
Lameijer M; Binderup T; van Leent MMT; Senders ML; Fay F; Malkus J; Sanchez-Gaytan BL; Teunissen AJP; Karakatsanis N; Robson P; Zhou X; Ye Y; Wojtkiewicz G; Tang J; Seijkens TTP; Kroon J; Stroes ESG; Kjaer A; Ochando J; Reiner T; Pérez-Medina C; Calcagno C; Fisher EA; Zhang B; Temel RE; Swirski FK; Nahrendorf M; Fayad ZA; Lutgens E; Mulder WJM; Duivenvoorden R
Nat Biomed Eng; 2018 May; 2(5):279-292. PubMed ID: 30936448
[TBL] [Abstract][Full Text] [Related]
18. Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis.
Aarts SA; Seijkens TT; Kusters PJ; van Tiel CM; Reiche ME; den Toom M; Beckers L; van Roomen CP; de Winther MP; Kooij G; Lutgens E
J Pathol; 2019 Apr; 247(4):471-480. PubMed ID: 30471110
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.
Portillo JA; Greene JA; Schwartz I; Subauste MC; Subauste CS
Immunology; 2015 Jan; 144(1):21-33. PubMed ID: 25051892
[TBL] [Abstract][Full Text] [Related]
20. p62 regulates CD40-mediated NFκB activation in macrophages through interaction with TRAF6.
Seibold K; Ehrenschwender M
Biochem Biophys Res Commun; 2015 Aug; 464(1):330-5. PubMed ID: 26133577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
